There is no abstract. The objectives are as follows:

The primary objective is to determine if immunotherapeutic agents improve survival in patients with metastatic or locally advanced renal cell carcinoma. Secondary objectives are to document and critically evaluate the effects of immunotherapy on other reported outcomes such as response rate, treatment toxicity, and quality‐of‐life.